To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia
Information source: Department of Veterans Affairs
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Schizophrenia; Schizoaffective Disorder
Intervention: Olanzapine (5 mg to 20 mg/day (Drug); Haloperidol (5 mg to 20 mg/day) (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Department of Veterans Affairs
Summary
Although currently marketed antipsychotic drugs are useful in the treatment of schizophrenia,
efficacy and safety profiles need to be improved. Forty to eighty percent of patients either
fail to respond or only partially respond to conventional antipsychotic agents. Secondary
symptoms may be unimproved even in patients who respond to treatment. A variety of adverse
events occur in patients receiving currently available agents. The severity of these events
contributes to the poor compliance that is observed in this patient population. Olanzapine is
a novel antipsychotic agent with a reduced incidence of extrapyramidal symptoms. Other side
effects are minimal.
Clinical Details
Official title: CSP #451 - The Clinical and Economic Impact of Olanzapine in the Traetment of Schizophrenia
Study design: Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Efficacy Study
Detailed description:
Primary Hypothesis: To determine if olanzapine is more cost effective than haloperidol for
the treatment of schizophrenia.
Secondary Hypothesis: Secondary objectives include evaluation of clinical efficacy, safety,
social and vocational functioning, family burden, compliance and satisfaction for olanzapine
relative to haloperidol.
Intervention: Olanzapine (5 mg to 20 mg/day), haloperidol (5 mg to 20 mg/day).
Primary Outcomes: Total inpatient hospital care costs are the primary outcome. Other major
outcomes are total social costs (cost of VA health care, non-VA services and other specified
social costs), efficacy measures (PANNS, BPRS, CGI Severity, and neurocognitive battery
scores) and safety measures (adverse events, ECG?s).
Study Abstract: Although currently marketed antipsychotic drugs are useful in the treatment
of schizophrenia, efficacy and safety profiles need to be improved. Forty to eighty percent
of patients either fail to respond or only partially respond to conventional antipsychotic
agents. Secondary symptoms may be unimproved even in patients who respond to treatment. A
variety of adverse events occur in patients receiving currently available agents. The
severity of these events contributes to the poor compliance that is observed in this patient
population. Olanzapine is a novel antipsychotic agent with a reduced incidence of
extrapyramidal symptoms. Other side effects are minimal.
Approximately 327 patients with schizophrenia or schizoaffective disorder were randomly
assigned to one of two treatment groups. One treatment group was prescribed olanzapine with
daily dosage ranging from 5 mg/day to 20 mg/day. The other treatment group was prescribed
haloperidol with daily dosage also ranging from 5 mg/day to 20 mg/day. A semi-structured
psychosocial case management treatment program is provided for all study patients. Patients
were recruited from 18 VA medical centers over a 24-month period and were followed for one
year. 18 patients were enrolled at one site that had its research program terminated during
the study. Because of questions regarding the circumstances that led to the termination,
these 18 patients will not be included in study analyses. The major objective of the study
is to determine if olanzapine is more cost effective than haloperidol. Secondary objectives
include evaluation of clinical efficacy, safety, social and vocational functioning, family
burden, compliance and satisfaction for olanzapine relative to haloperidol.
MANUSCRIPT: Primary manuscript published in JAMA, November 2003.
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Patients with schizophrenia or schizoaffective disorder.
Locations and Contacts
Vamc - Tuscaloosa, Al, Tuscaloosa, Alabama 35404, United States
Vamc - Tuskegee, Al, Tuskegee, Alabama 36093, United States
Vamc - Palo Alto, Ca, Palo Alto, California 94304, United States
Vamc - West Haven,Ct, West Haven, Connecticut 06516, United States
Vamc - Bay Pines, Fl, Bay Pines, Florida 33744, United States
Vamc - Miami, Fl, Miami, Florida 33125, United States
Vamc - Augusta, Ga, Augusta, Georgia 30904-6285, United States
Vamc - Indianapolis, in, Indianapolis, Indiana 46202, United States
Vamc - Perry Point, Md, Perry Point, Maryland 21902, United States
Vamc - Bedford, Ma, Bedford, Massachusetts 01730, United States
Vamc - Detroit, Mi, Detroit, Michigan 48201, United States
New Jersey Hcs - Lyons, Nj, Lyons, New Jersey 07939, United States
VAMC - Albuquerque, NM, Albuquerque, New Mexico 87108, United States
Vamc - Montrose, Ny, Montrose, New York 10548-0100, United States
Vamc - New York, Ny, New York, New York 10010, United States
Vamc - Durham, Nc, Durham, North Carolina 27705, United States
Vamc - Brecksville, Oh, Brecksville, Ohio 44141, United States
Vamc - Philadelphia, Pa, Philadelphia, Pennsylvania 19104, United States
Vamc - Pittsburgh, Pa, Pittsburgh, Pennsylvania 15206-1297, United States
Additional Information
Starting date: March 1998
Ending date: June 2001
Last updated: February 2, 2007
|
